RGS Share Price Performance
AU$0
0.00 (0.00%)
Price AU$0
Share Pricen/a
Regeneus Ltd Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
RGS Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Regeneus Ltd Key Details
Last Reported Earnings
Dec 31, 2023
Next Reporting Earnings
n/a
- -0.0012
- 100.00%
- -37.03%
- 0%
About RGS
- Founded
- 2007
- Employees
- n/a
- CEO
- WebsiteView website
Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company’s platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.
